Press releases
- Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2024 Annual Meeting
- Moffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer Therapeutics
- Fulgent Reports First Quarter 2024 Financial Results
- Fulgent Genetics to Announce First Quarter 2024 Financial Results on Friday, May 3, 2024
- Fulgent Reports Fourth Quarter and Full Year 2023 Financial Results
More ▼
Key statistics
As of last trade Fulgent Genetics Inc (FLGT*:MEX) traded at 376.00, 8.98% above its 52-week low of 345.01, set on May 02, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | 356.76 |
Previous close | 355.27 |
Average volume | 111.33 |
---|---|
Shares outstanding | 29.92m |
Free float | 20.20m |
P/E (TTM) | -- |
Market cap | 632.60m USD |
EPS (TTM) | -5.57 USD |
Data delayed at least 20 minutes, as of May 13 2024 12:30 BST.
More ▼